用于癌症重新靶向的表达嵌合抗原受体的自然杀伤细胞
CAR-Expressing Natural Killer Cells for Cancer Retargeting.
作者信息
Kloess Stephan, Kretschmer Anna, Stahl Lilly, Fricke Stephan, Koehl Ulrike
机构信息
Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
Institute for Cellular Therapeutics, ATMP-GMPDU, Hannover Medical School, Hannover, Germany.
出版信息
Transfus Med Hemother. 2019 Feb;46(1):4-13. doi: 10.1159/000495771. Epub 2019 Feb 5.
Abstract
Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on clinicaltrial.gov. In contrast to CAR-T cells, natural killer (NK) cells can be used from allogeneic donors as an "off the shelf product" and provide alternative candidates for cancer retargeting. This review summarises preclinical results of CAR-engineered NK cells using both primary human NK cells and the cell line NK-92, and provides an overview about the first clinical CAR-NK cell studies targeting haematological malignancies and solid tumours, respectively.
摘要
自2017年Kymriah®和Yescarta®获批且取得显著成功以来，研究嵌合抗原受体修饰的自体T细胞安全性和有效性的临床试验数量一直在不断增加。目前，clinicaltrial.gov上列出了200多项临床试验。与CAR-T细胞不同，自然杀伤（NK）细胞可作为“现成产品”从异体供体获取，为癌症重定向提供了替代候选方案。本综述总结了使用原代人NK细胞和NK-92细胞系的CAR工程化NK细胞的临床前结果，并分别概述了针对血液系统恶性肿瘤和实体瘤的首批CAR-NK细胞临床研究。
相似文献
1
CAR-Expressing Natural Killer Cells for Cancer Retargeting.
Transfus Med Hemother. 2019 Feb;46(1):4-13. doi: 10.1159/000495771. Epub 2019 Feb 5.
2
Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.
Clin Oncol (R Coll Radiol). 2023 Mar;35(3):153-162. doi: 10.1016/j.clon.2022.10.019. Epub 2022 Nov 24.
3
CAR-expressing NK cells for cancer therapy: a new hope.
Biosci Trends. 2020 Nov 4;14(5):354-359. doi: 10.5582/bst.2020.03308. Epub 2020 Sep 6.
4
Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review).
Exp Ther Med. 2021 Apr;21(4):340. doi: 10.3892/etm.2021.9771. Epub 2021 Feb 10.
5
Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):200-215. doi: 10.1016/j.bbcan.2018.01.005. Epub 2018 Jan 31.
6
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Front Immunol. 2018 Feb 15;9:283. doi: 10.3389/fimmu.2018.00283. eCollection 2018.
7
Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Hum Gene Ther. 2019 Apr;30(4):381-401. doi: 10.1089/hum.2018.247. Epub 2019 Mar 18.
8
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
Cancer Immunol Res. 2018 Apr;6(4):467-480. doi: 10.1158/2326-6066.CIR-17-0207. Epub 2018 Feb 19.
9
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.
Front Immunol. 2017 May 18;8:533. doi: 10.3389/fimmu.2017.00533. eCollection 2017.
10
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.
Front Oncol. 2021 Aug 6;11:720501. doi: 10.3389/fonc.2021.720501. eCollection 2021.
引用本文的文献
1
CAR-NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor.
Immun Inflamm Dis. 2025 Jun;13(6):e70210. doi: 10.1002/iid3.70210.
2
Evaluating the Influence of Different Serum-Free Culture Conditions on the Production and Function of Natural Killer Cell-Derived Extracellular Vesicles.
J Extracell Biol. 2025 Apr 25;4(4):e70049. doi: 10.1002/jex2.70049. eCollection 2025 Apr.
3
Prospects for potential therapy targeting immune‑associated factors in endometriosis (Review).
Mol Med Rep. 2025 Mar;31(3). doi: 10.3892/mmr.2024.13422. Epub 2024 Dec 24.
4
Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.
J Nanobiotechnology. 2024 Sep 10;22(1):552. doi: 10.1186/s12951-024-02746-4.
5
Augmenting the Antitumor Efficacy of Natural Killer Cells via SynNotch Receptor Engineering for Targeted IL-12 Secretion.
Curr Issues Mol Biol. 2024 Mar 28;46(4):2931-2945. doi: 10.3390/cimb46040183.
6
A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases.
Med Oncol. 2024 Apr 24;41(6):127. doi: 10.1007/s12032-024-02362-0.
7
Reovirus infection of tumor cells reduces the expression of NKG2D ligands, leading to impaired NK-cell cytotoxicity and functionality.
Front Immunol. 2023 Sep 11;14:1231782. doi: 10.3389/fimmu.2023.1231782. eCollection 2023.
8
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.
Front Immunol. 2023 Mar 21;14:1142597. doi: 10.3389/fimmu.2023.1142597. eCollection 2023.
9
Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.
Blood Rev. 2023 Jul;60:101073. doi: 10.1016/j.blre.2023.101073. Epub 2023 Mar 12.
10
Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B.
Int J Mol Sci. 2023 Feb 4;24(4):3129. doi: 10.3390/ijms24043129.
本文引用的文献
1
Making CAR T Cells a Solid Option for Solid Tumors.
Front Immunol. 2018 Nov 8;9:2593. doi: 10.3389/fimmu.2018.02593. eCollection 2018.
2
Clinical use of lentiviral vectors.
Leukemia. 2018 Jul;32(7):1529-1541. doi: 10.1038/s41375-018-0106-0. Epub 2018 Mar 22.
3
Advances in immunotherapy for acute myeloid leukemia.
Future Oncol. 2018 Apr;14(10):963-978. doi: 10.2217/fon-2017-0459. Epub 2018 Mar 15.
4
Investigational CD33-targeted therapeutics for acute myeloid leukemia.
Expert Opin Investig Drugs. 2018 Apr;27(4):339-348. doi: 10.1080/13543784.2018.1452911. Epub 2018 Mar 15.
5
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Front Immunol. 2018 Feb 15;9:283. doi: 10.3389/fimmu.2018.00283. eCollection 2018.
6
T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G.
Oncotarget. 2017 Dec 22;9(5):6536-6549. doi: 10.18632/oncotarget.23815. eCollection 2018 Jan 19.
7
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
Cancer Immunol Res. 2018 Apr;6(4):467-480. doi: 10.1158/2326-6066.CIR-17-0207. Epub 2018 Feb 19.
8
CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Hum Gene Ther. 2018 May;29(5):626-639. doi: 10.1089/hum.2017.241. Epub 2018 Mar 19.
9
Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines.
Oncoimmunology. 2017 Dec 26;7(3):e1407898. doi: 10.1080/2162402X.2017.1407898. eCollection 2018.
10
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.
Zotero 插件